Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 14/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.45 |
| ▸ | GUSB | P08236 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1995841 | 0.74 | DPP4 (0.46) | DPP4DPP8ALPL | |
| SCHEMBL8277153 | 0.68 | DPP4 (0.64) | DPP4DPP8PARP1 | |
| SCHEMBL3034134 | 0.65 | PARP1 (0.67) | KDM4EPARP1 | |
| SCHEMBL30013261 | 0.65 | PARP1 (0.67) | KDM4EPARP1 | |
| SCHEMBL3671768 | 0.65 | CSNK2A2 (0.41) | KDM4EPARP1 | |
| SCHEMBL3423565 | 0.65 | KDM4E (0.50) | KDM4EPARP1 | |
| SCHEMBL1996410 | 0.64 | DPP4 (0.47) | DPP4DPP8 | |
| SCHEMBL1997291 | 0.64 | DPP4 (0.44) | DPP4DPP8PARP1 | |
| SCHEMBL464507 | 0.63 | AHR (0.64) | KDM4E | |
| SCHEMBL29624840 | 0.63 | AHR (0.64) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249611-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-10-25 | — | — | US | claimed |
| WO-2007112347-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-04 | — | — | WO | claimed |
| US-7960384-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-7960384-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-7960384-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20070249611-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249611-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249611-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-10-25 | — | — | US | disclosed |
| WO-2007112347-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249611-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | DPP3, DPP4, DPP7 | DPP4 2/4885DPP8 5/4885GUSB 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.